SCHEMBL8112939

SCHEMBL8112939

CCCCOCCCC=O

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.62
FAAH O00519 2/20 0.50
TRPV1 Q8NER1 2/20 0.50
CYP3A4 P08684 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HIF1A Q16665 1/20 0.43
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 1/20 0.39
ATM Q13315 1/20 0.38
MEN1 O00255 1/20 0.38
THRB P10828 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2903076 0.98 TSHR (0.59) TSHRFAAHTRPV1CYP3A4ALDH1A1
SCHEMBL8840933 0.93 TSHR (0.61) TSHRFAAHTRPV1CYP3A4ALDH1A1
SCHEMBL11498365 0.93 TSHR (0.61) TSHRFAAHTRPV1CYP3A4ALDH1A1
SCHEMBL13183507 0.91 TSHR (0.65) TSHRFAAHTRPV1CYP3A4ALDH1A1
SCHEMBL13474797 0.91 TSHR (0.65) TSHRFAAHTRPV1MAPTMEN1
SCHEMBL19040831 0.91 TSHR (0.65) TSHRFAAHTRPV1CYP3A4ALDH1A1
SCHEMBL820598 0.91 TSHR (0.65) TSHRFAAHTRPV1MAPTMEN1
SCHEMBL1301661 0.91 TSHR (0.65) TSHRFAAHTRPV1MAPTMEN1
SCHEMBL27916603 0.91 TSHR (0.65) TSHRFAAHTRPV1CYP3A4ALDH1A1
SCHEMBL883374 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001943-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM Aventis Pharma S.A. (FR) 2000-05-24 EP claimed
WO-1999003843-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1999-01-28 WO claimed
US-11773061-B2 Cyclic lipids and methods of use thereof RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-10-03 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-2883858-B1 METHOD FOR PRODUCING HEXAHYDROFUROFURANOL DERIVATIVE SUMITOMO CHEMICAL CO (JP) 2017-12-27 EP disclosed
US-9809566-B2 Organocatalytic process for asymmetric synthesis of decanolides COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2017-11-07 US disclosed
US-9765048-B2 Organocatalytic process for asymmetric synthesis of decanolides COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2017-09-19 US disclosed
US-9670232-B2 Molecular precursor compounds for zinc-group 13 mixed oxide materials TRANSTRON SOLUTIONS LLC (US) 2017-06-06 US disclosed
US-9455142-B2 Molecular precursor compounds for ABIGZO zinc-group 13 mixed oxide materials TRANSTRON SOLUTIONS LLC (US) 2016-09-27 US disclosed
US-20160272608-A1 ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-09-22 US disclosed
US-20160272609-A1 ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-09-22 US disclosed
WO-1988005767-A1 HYDROGENATION PROCESS DAVY MCKEE (LONDON) LIMITED (GB) 1988-08-11 WO disclosed
EP-0277168-A1 PROCESS FOR THE CO-PRODUCTION OF BUTANE-1,4-DIOL AND $i(GAMMA)-BUTYROLACTONE DAVY McKEE (LONDON) LIMITED (GB) 1988-08-10 EP disclosed
WO-1988000937-A1 PROCESS FOR THE CO-PRODUCTION OF BUTANE-1,4-DIOL AND GAMMA-BUTYROLACTONE DAVY MCKEE (LONDON) LIMITED (GB) 1988-02-11 WO disclosed
WO-1987007598-A1 PROCESS FOR HYDROGENATING AN UNSATURATED ORGANIC COMPOUND DAVY MCKEE (LONDON) LIMITED (GB) 1987-12-17 WO disclosed
EP-0223814-A1 PROCESS FOR THE PRODUCTION OF $i(GAMMA)-BUTYROLACTONE DAVY McKEE (LONDON) LIMITED (GB) 1987-06-03 EP disclosed
WO-1986007358-A1 PROCESS FOR THE PRODUCTION OF GAMMA-BUTYROLACTONE DAVY MCKEE (LONDON) LIMITED (GB) 1986-12-18 WO disclosed
EP-0204730-A1 PROCESS FOR THE PRODUCTION OF BUTANE-1,4-DIOL DAVY McKEE (LONDON) LIMITED (GB) 1986-12-17 EP disclosed
WO-1986003189-A1 PROCESS FOR THE PRODUCTION OF BUTANE-1,4-DIOL DAVY MCKEE (LONDON) LIMITED (GB) 1986-06-05 WO disclosed
EP-0024532-A1 Tert. butoxybutanales and butanoles and bis-tert. butoxy-pentanales and pentanoles, their production and their use as perfumes BASF Aktiengesellschaft (DE) 1981-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272609-A1 ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES CDC14A, CDC14B, DDOST TSHR 4683/4885FAAH 3873/4885TRPV1 1685/4885
US-11773061-B2 Cyclic lipids and methods of use thereof SGMS1, SGMS2, LNPEP TSHR 2474/4885FAAH 2169/4885TRPV1 3200/4885
US-20160272608-A1 ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES CDC14A, CDC14B, DDOST TSHR 4683/4885FAAH 3873/4885TRPV1 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.